Cervical Dystonia Therapeutics Market by Product and Geography - Forecast and Analysis 2021-2025

Published: Jan 2022 Pages: 120 SKU: IRTNTR72070

The cervical dystonia therapeutics market share is expected to increase to USD 154.77 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 5.43%.

This cervical dystonia therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers cervical dystonia therapeutics market segmentation by the follwing:

  • Product - Botulinum toxins and other therapeutics 
  • Geography (North America, Europe, Asia, and ROW

The cervical dystonia therapeutics market report also offers information on several market vendors, including AbbVie Inc., Akorn Inc., Eisai Co. Ltd., Galderma SA, Ipsen Pharma, Lannett Co. Inc., Medytox Inc., Merz Pharma GmbH, and Co. KGaA, Revance Therapeutics Inc., and Supernus Pharmaceuticals Inc. among others.

What will the Cervical Dystonia Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Cervical Dystonia Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Cervical Dystonia Therapeutics Market: Key Drivers, Trends, and Challenges

The expected approval of late-stage pipeline molecules is notably driving the cervical dystonia therapeutics market growth, although factors such as the availability of alternative therapies may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the cervical dystonia therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Cervical Dystonia Therapeutics Market Driver

The expected approval of late-stage pipeline molecules is one of the key drivers supporting cervical dystonia therapeutics market growth. Despite the significant research undertaken over the past several decades, a treatment that is promising and has fewer side effects is not yet available for cervical dystonia. This is encouraging pharmaceutical companies to focus on the development of promising therapeutics for the treatment of cervical dystonia. For instance, Revance Therapeutics commenced an open-label, multi-center Phase III trial to evaluate the long-term safety and efficacy of repeat treatments of daxibotulinumtoxinA in adults who have isolated cervical dystonia, which was completed in January 2021. The company received approval from the US FDA in April 2021. Once these molecules are launched during the forecast period, the global cervical dystonia therapeutics market should witness strong value growth from these newly launched therapeutics.

Key Cervical Dystonia Therapeutics Market Trend

The reimbursement for botulinum neurotoxin injections is another factor supporting cervical dystonia therapeutics market growth. Several reimbursement programs are available to help people access the high-cost botulinum neurotoxin therapy for the treatment of cervical dystonia. These reimbursement programs help patients with or without medical insurance to achieve appropriate reimbursement for their treatment with botulinum toxins. For instance, ALLERGAN, the manufacturer of BOTOX, sponsors a comprehensive reimbursement program called as BOTOX Reimbursement Solutions Program. This program includes a BOTOX Hotline and BOTOX Patient Assistance Program to assist patients who are receiving BOTOX injection treatment. The BOTOX Patient Assistance Program helps financially eligible patients gain access to BOTOX. Thus, several reimbursement programs aid the eligible patients for the high-cost botulinum toxins treatment and boost the global cervical dystonia market growth over the forecast period.

Key Cervical Dystonia Therapeutics Market Challenge

The availability of alternative therapies may hinder the cervical dystonia therapeutics market growth during the forecast period. For the treatment of cervical dystonia, botulinum toxins and other therapeutics are mainly used. However, the low success rate and temporary cure of these therapeutics lead people to prefer alternative therapies such as DBS surgery. It is a highly effective procedure for cervical dystonia and is appropriate for patients who stop showing a response to botulinum toxin. The sensory trick is another option available for the treatment of cervical dystonia. The key to treatment is to get it addressed as soon as possible to avoid the progress of cervical dystonia symptoms. Hence, the available alternative treatments are expected to strongly hamper the growth of the cervical dystonia therapeutics market over the forecast period.

This cervical dystonia therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the cervical dystonia therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the cervical dystonia therapeutics market during the forecast period.

Who are the Major Cervical Dystonia Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • AbbVie Inc.
  • Akorn Inc.
  • Eisai Co. Ltd.
  • Galderma SA
  • Ipsen Pharma
  • Lannett Co. Inc.
  • Medytox Inc.
  • Merz Pharma GmbH and Co. KGaA
  • Revance Therapeutics Inc.
  • Supernus Pharmaceuticals Inc.

 

This statistical study of the cervical dystonia therapeutics market encompasses successful business strategies deployed by the key vendors. The cervical dystonia therapeutics market is concentrated and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

  • AbbVie Inc. - The company offers cervical dystonia therapeutics namely BOTOX through its subsidiary Allergan Inc.
  • AbbVie Inc. - Under the unified segment, the company conducts research and development, manufacturing, commercialization and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long term strategic goals.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The cervical dystonia therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Cervical Dystonia Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the cervical dystonia therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the pharmaceuticals market includes the following core components:

  • Research and development (R&D) and drug discovery
  •  Integration and product development
  • Manufacturing
  • Outbound logistics
  • Marketing and sales
  • Support services
  • Innovation

The report has further elucidated on other innovative approaches being followed by service providers to ensure a sustainable market presence.

 

Which are the Key Regions for Cervical Dystonia Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

38% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the cervical dystonia therapeutics market in North America. Market growth in this region will be faster than the growth of the market in ROW.

The presence of the highest adult population will facilitate the cervical dystonia therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, countries such as the US and Canada in North America were severely affected by the COVID-19 pandemic. The rise in the incidence of COVID-19 across various countries in North America influenced governments to introduce emergency legislation, which included restrictions on several business activities. This led to the shutdown of manufacturing units of several industries in 2020. A few essential industries, such as pharmaceutical companies, were allowed to operate at the usual utilization rate. However, as most of these pharmaceutical companies also focused on developing COVID-19 vaccines and manufacturing other drugs to support the medical crisis associated with the COVID-19 pandemic, the production volume of therapeutic drugs other than COVID-19 declined to a certain extent during the first few months of 2020. 

What are the Revenue-generating Product Segments in the Cervical Dystonia Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The cervical dystonia therapeutics market share growth by the botulinum toxins segment will be significant during the forecast period. The growth of the botulinum toxins segment is primarily driven by the increasing usage of botulinum toxins A and B for the treatment of cervical dystonia. For instance, currently, MEDITOXIN and daxibotulinumtoxinA are in the Phase III stage of development for the treatment of cervical dystonia and are expected to enter into the market and generate significant revenue during the forecast period. This, in turn, will enhance the growth of the global cervical dystonia therapeutics market over the forecast period. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the cervical dystonia therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

 

Cervical Dystonia Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 5.43%

Market growth 2021-2025

$ 154.77 million

Market structure

Concentrated

YoY growth (%)

4.15

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 38%

Key consumer countries

US, Canada, Germany, China, and UK

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

AbbVie Inc., Akorn Inc., Eisai Co. Ltd., Galderma SA, Ipsen Pharma, Lannett Co. Inc., Medytox Inc., Merz Pharma GmbH and Co. KGaA, Revance Therapeutics Inc., and Supernus Pharmaceuticals Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Cervical Dystonia Therapeutics Market Report?

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive cervical dystonia therapeutics market growth during the next five years
  • Precise estimation of the cervical dystonia therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the cervical dystonia therapeutics industry across North America, Europe, Asia, and ROW
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of cervical dystonia therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

***1. Executive Summary                           

                **1.1     Market Overview            

                                *Exhibit 01:  Key Finding 1

                                *Exhibit 02:  Key Finding 2

                                *Exhibit 03:  Key Finding 3

                                *Exhibit 04:  Key Finding 5

                                *Exhibit 05:  Key Finding 6

                                *Exhibit 06:  Key Finding 7

                                *Exhibit 07:  Key Finding 8

***2. Market Landscape              

                **2.1 Market ecosystem           

                                *2.1.1 Parent Market

                                *Exhibit 08:  Parent market

                                *Exhibit 09:  Market characteristics

                **2.2 Value Chain Analysis          

                                *Exhibit 10:  Value Chain Analysis: Pharmaceuticals

                                *2.2.1    Research and development (R&D) and drug discovery

                                *2.2.2    Integration and product development

                                *2.2.3    Manufacturing

                                *2.2.4    Outbound logistics

                                *2.2.5    Marketing and sales

                                *2.2.6    Support services

                             *2.2.7   Innovation

***3. Market Sizing                       

                **3.1 Market definition

                                *Exhibit 11:  Offerings of vendors included in the market definition

                **3.2 Market segment analysis 

                                *Exhibit 12:  Market segments

                **3.3 Market size 2021 

                **3.4 Market outlook: Forecast for 2020 - 2025 

                                *3.4.1Estimating growth rates for emerging and high-growth markets

                                *3.4.2Estimating growth rates for mature markets

                                *Exhibit 13:  Global - Market size and forecast 2020 - 2025 ($ million)

                                *Exhibit 14:  Global market: Year-over-year growth 2020 - 2025 (%)

***4. Five Forces Analysis                          

                **4.1 Five Forces Summary        

                                *Exhibit 15:  Five forces analysis 2020 & 2025

                **4.2 Bargaining power of buyers           

                                *Exhibit 16: Bargaining power of the buyer

                **4.3 Bargaining power of suppliers       

                                *Exhibit 17: Bargaining power of the supplier

                **4.4 Threat of new entrants    

                                *Exhibit 18: Threat of new entrants

                **4.5 Threat of substitutes         

                                *Exhibit 19: Threat of substitutes

                **4.6 Threat of rivalry   

                                *Exhibit 20: Threat of rivalry

                **4.7 Market condition

                                *Exhibit 21: Market condition - Five forces 2020

***5. Market Segmentation by Product

              **5.1 Market segments

                                *Exhibit 22:  Product- Market share 2020-2025 (%)

                **5.2 Comparison by Product    

                                *Exhibit 23:  Comparison by Product

                **5.3 Botulinum toxins - Market size and forecast 2020-2025       

                                *Exhibit 24:  Botulinum toxins - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 25:  Botulinum toxins - Year-over-year growth 2020-2025 (%)

                **5.4 Other therapeutics - Market size and forecast 2020-2025   

                                *Exhibit 26:  Other therapeutics - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 27:  Other therapeutics - Year-over-year growth 2020-2025 (%)

                **5.5 Market opportunity by Product    

                                *Exhibit 28:  Market opportunity by Product

***6. Customer landscape                         

                                *Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria

                **6.1 Overview

                                *Exhibit 29:  Customer landscape

***7. Geographic Landscape                     

                **7.1 Geographic segmentation

                                *Exhibit 30:  Market share by geography 2020-2025 (%)

                **7.2 Geographic comparison   

                                *Exhibit 31:  Geographic comparison

                **7.3 North America - Market size and forecast 2020-2025           

                                *Exhibit 32:  North America - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 33:  North America - Year-over-year growth 2020-2025 (%)

                **7.4 Europe - Market size and forecast 2020-2025          

                                *Exhibit 34:  Europe - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 35:  Europe - Year-over-year growth 2020-2025 (%)

                **7.5 Asia - Market size and forecast 2020-2025

                                *Exhibit 36:  Asia - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 37:  Asia - Year-over-year growth 2020-2025 (%)

                **7.6 ROW- Market size and forecast 2020-2025               

                                *Exhibit 38:  ROW - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 39:  ROW - Year-over-year growth 2020-2025 (%)

                **7.7 Key leading countries        

                                *Exhibit 40:  Key leading countries

                **7.8 Market opportunity by geography

                                *Exhibit 41:  Market opportunity by geography ($ million)

***8. Drivers, Challenges, and Trends                   

                **8.1 Market drivers     

                                *8.1.1    Expected approval of late-stage pipeline molecules

                                *8.1.2    Increasing awareness about cervical dystonia

                                *8.1.3    Rising middle-age group population

                **8.2 Market challenges              

                                *8.2.1    Availability of alternate therapies

                                *8.2.2    Side effects associated with the available medications

                                *8.2.3    High cost of first-line treatment medicines

                                *Exhibit 42:  Impact of drivers and challenges

                **8.3 Market trends      

                                *8.3.1    Reimbursement for botulinum neurotoxin injections

                                *8.3.2    Strategic alliances

                                *8.3.3    Biosimilars development for cervical dystonia

***9. Vendor Landscape                             

                **9.1 Overview

                                *Exhibit 43:  Vendor landscape

                **9.2 Landscape disruption        

                                *Exhibit 44:  Landscape disruption

                                *Exhibit 45: Industry Risk

                **9.3 Competitive Scenario        

***10. Vendor Analysis               

                **10.1 Vendors covered              

                                *Exhibit 46: Vendors covered

                **10.2 Market positioning of vendors    

                                *Exhibit 47: ?Market positioning of vendors?

                **10.3 AbbVie Inc.         

                                *Exhibit 48:  AbbVie Inc. - Overview

                                *Exhibit 49:  AbbVie Inc. - Business segments

                                *Exhibit 50:  AbbVie Inc. - Key offerings

                                *Exhibit 51:  AbbVie Inc. - Segment focus

                *10.4 Akorn Inc.

                                *Exhibit 52:  Akorn Inc. - Overview

                                *Exhibit 53:  Akorn Inc. - Product and service

                                *Exhibit 54:  Akorn Inc. - Key offerings

                                *Exhibit 55:  Akron Inc. – Key news

                *10.5 Eisai Co. Ltd.

                                *Exhibit 56:  Eisai Co. Ltd. - Overview

                                *Exhibit 57:  Eisai Co. Ltd. - Business segments

                                *Exhibit 58:  Eisai Co. Ltd. - Key offerings

                                *Exhibit 59:  Eisai Co. Ltd. - Segment focus

                **10.6 Galderma SA      

                                *Exhibit 60:  Galderma SA - Overview

                                *Exhibit 61:  Galderma SA - Product and service

                                *Exhibit 62:  Galderma SA - Key offerings

                **10.7 Ipsen Pharma     

                                *Exhibit 63:  Ipsen Pharma  - Overview

                                *Exhibit 64:  Ipsen Pharma  - Business segments

                                *Exhibit 65:  Ipsen Pharma  - Key offerings

                                *Exhibit 66:  Ipsen Pharma  - Segment focus

                **10.8 Lannett Co. Inc. 

                                *Exhibit 67:  Lannett Co. Inc. - Overview

                                *Exhibit 68:  Lannett Co. Inc. - Business segments

                                *Exhibit 69:  Lannett Co. Inc. - Key offerings

                                *Exhibit 70:  Lannett Co. Inc. - Segment focus

                **10.9 Medytox Inc.      

                                *Exhibit 71:  Medytox Inc. - Overview

                                *Exhibit 72:  Medytox Inc. - Business segments

                                *Exhibit 73:  Medytox Inc. - Key offerings

                                *Exhibit 74:  Medytox Inc. - Segment focus

                **10.10 Merz Pharma GmbH and Co. KGaA         

                                *Exhibit 75:  Merz Pharma GmbH and Co. KGaA - Overview

                                *Exhibit 76:  Merz Pharma GmbH and Co. KGaA - Product and service

                                *Exhibit 77:  Merz Pharma GmbH and Co. KGaA - Key offerings

                **10.11 Revance Therapeutics Inc.         

                                *Exhibit 78:  Revance Therapeutics Inc. - Overview

                                *Exhibit 79:  Revance Therapeutics Inc. - Product and service

                                *Exhibit 80:  Revance Therapeutics Inc. - Key offerings

                **10.12 Supernus Pharmaceuticals Inc. 

                                *Exhibit 81:  Supernus Pharmaceuticals Inc. - Overview

                                *Exhibit 82:  Supernus Pharmaceuticals Inc. - Business segments

                                *Exhibit 83:  Supernus Pharmaceuticals Inc. – Key news

                                *Exhibit 84:  Supernus Pharmaceuticals Inc. - Key offerings

                                *Exhibit 85:  Supernus Pharmaceuticals Inc. - Segment focus

***11. Appendix                            

                **11.1 Scope of the report         

                                *11.1.1 ????Market definition

                                *11.1.2 ????Objectives

                                *11.1.3 ????Notes and caveats

                **11.2 Currency conversion rates for US$            

                                *Exhibit 86: ?Currency conversion rates for US$?

                **11.3 Research Methodology 

                                *Exhibit 87: ?Research Methodology

                                *Exhibit 88: ??Validation techniques employed for market sizing?

                                *Exhibit 89: ??Information sources

                **11.4 List of abbreviations        

                                *Exhibit 90: List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases

DATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts

REPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape

PURCHASE FULL REPORT OF

cervical dystonia therapeutics market

QUICK BUY

Key Questions Answered

  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis